Which has the lower trailing P/E, CAI or KRYS?

KRYS has the lower trailing P/E: CAI trades at 81.14 and KRYS at 40.51. P/E is one valuation measure and does not by itself establish which business is cheaper.

Is CAI or KRYS more profitable?

KRYS runs the higher net margin — CAI at 10.62% versus KRYS at 54.82%.

Caris Life Sciences, Inc. (CAI) vs Krystal Biotech, Inc. (KRYS)

A side-by-side comparison of Caris Life Sciences, Inc. and Krystal Biotech, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

CAI

Caris Life Sciences, Inc.

$8.21B

$29.04HealthcareDelayed quote: Oct 6, 2026, 10:55 AM EDT

KRYS

Krystal Biotech, Inc.

$9.53B

$323.27HealthcareDelayed quote: Oct 6, 2026, 10:50 AM EDT

Total return — CAI vs KRYS

growth of $100 · dividends reinvested · last 1y

CAI +8.5% (+8.5%/yr)KRYS +151.7% (+151.7%/yr)KRYS compounded faster over this window

CAI KRYS

CAI vs KRYS: by the numbers

•KRYS is the larger company ($9.53B vs $8.21B market cap).
•KRYS trades at the lower trailing earnings multiple (40.51 vs 81.14 P/E), one valuation lens rather than an overall verdict.
•KRYS converts more revenue to profit (54.82% vs 10.62% net margin).

Metrics side by side

Valuation

Metric	CAI	KRYS
P/E ratio	81.14	40.51
Forward P/E	250.29	42.49
P/S ratio	8.30	21.64
P/B ratio	13.87	7.01
EV / EBITDA	45.80	44.58
FCF yield	1.78%	2.70%

Profitability

Metric	CAI	KRYS
Gross margin	69.66%	93.34%
Operating margin	5.56%	44.93%
Net margin	10.62%	54.82%
ROE	17.77%	17.77%
ROIC	14.76%	14.41%

Growth (annualized)

Metric	CAI	KRYS
Revenue CAGR (5Y)	26.15%	N/A
Total return CAGR (5Y)	N/A	44.28%

Frequently asked

Which has the lower trailing P/E, CAI or KRYS?: KRYS has the lower trailing P/E: CAI trades at 81.14 and KRYS at 40.51. P/E is one valuation measure and does not by itself establish which business is cheaper.
Is CAI or KRYS more profitable?: KRYS runs the higher net margin — CAI at 10.62% versus KRYS at 54.82%.

Go deeper

Full CAI analysis Full KRYS analysis Interactive comparison tool

Dig into the metrics

Caris Life Sciences P/E ratio Krystal Biotech P/E ratio Caris Life Sciences ROE Krystal Biotech ROE Caris Life Sciences operating margin Krystal Biotech operating margin Caris Life Sciences revenue growth Krystal Biotech revenue growth Caris Life Sciences free cash flow Krystal Biotech free cash flow

Caris Life Sciences & Krystal Biotech appear in these rankings

Fastest Revenue Growth Stocks Highest Operating Margin Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.